Zhongsheng Pharmaceutical (002317.SZ): The clinical trial progress, review, and approval results of innovative drug research and development projects are uncertain.

Zhixingtong Finance APP News, Zhongsheng Pharmaceuticals (002317.SZ) announced that the company is currently advancing two Phase III clinical trials for Anglardivir granules to treat children aged 2-11 with uncomplicated type A influenza and Anglardivir tablets to treat teenagers aged 12-17 with uncomplicated type A influenza, a Phase III clinical trial for RAY1225 injection to treat obese/overweight patients, and two Phase III clinical trials for RAY1225 injection to treat patients with type 2 diabetes. The progress of innovative drug R&D projects, the results of evaluation and approval, and the future market competition landscape all have certain uncertainties. There is uncertainty about whether the drugs can be approved for marketing, the time of approval for marketing, and the production and sales situation after market approval.